Guglielmana Veronica, Fusi Francesco Maria, Giardini Valentina, Cocito Federica, Gambacorti-Passerini Carlo
Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Hematology Division and Bone Marrow Unit, IRCCS San Gerardo dei Tintori, Monza, Italy.
Hematol Oncol. 2025 Jan;43(1):e70038. doi: 10.1002/hon.70038.
Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy. These cases demonstrate crizotinib potential to support conception without compromising disease control, even in the absence of specific guidelines on treatment discontinuation.
间变性淋巴瘤激酶阳性（ALK+）间变性大细胞淋巴瘤（ALCL）通常影响年轻个体，尽管对细胞毒性药物反应率高，但超过50%的患者会复发。克唑替尼改善了治疗结果，但对于有生育意愿的患者，其管理仍是一个问题。本研究首次描述了4例在使用克唑替尼治疗ALK+ALCL期间成功妊娠的病例：1例女性患者通过辅助生殖技术（ART）成功妊娠2次，期间暂时停用克唑替尼并维持完全缓解（CR）；1例男性患者在持续治疗期间自然受孕。这些病例表明，即使在缺乏关于停药的具体指南的情况下，克唑替尼在不影响疾病控制的前提下支持受孕的潜力。
